Cooley, Latham Handle $686M AMAG-Allos Merger

Law360, New York (July 20, 2011, 3:17 PM EDT) -- Drug developers AMAG Pharmaceuticals Inc. and Allos Therapeutics Inc. announced Wednesday an all-stock merger valued at about $686 million that is expected to strengthen their product lines and streamline their costs.

Massachusetts-based AMAG and Colorado-based Allos said that by combining, they'll save between $55 million and $60 million, most of which will be realized in the first fiscal year after the merger closes.

"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported...
To view the full article, register now.